In Re: Purdue Pharma L.P.

Court of Appeals for the Second Circuit·Decided May 30, 2023·No. 22-110-bk (L)·Published

Opinion

22-110-bk (L)

In re: Purdue Pharma L.P.

1 In the 2 United States Court of Appeals 3 For the Second Circuit 4 _____________________________________

5 AUGUST TERM 2021 6 7 ARGUED: APRIL 29, 2022 8 DECIDED: MAY 30, 2023 9 10 NOS. 22-110-bk (L), 22-113-bk, 22-115-bk, 22-116-bk, 22-117-bk, 22-119-bk, 11 22-121-bk, 22-299-bk, 22-203-bk 12 _____________________________________

13 In Re: Purdue Pharma L.P., Purdue Pharma Inc, Purdue Transdermal 14 Technologies L.P., Purdue Pharma Manufacturing L.P., Purdue Pharmaceuticals 15 L.P., Imbrium Therapeutics L.P., Adlon Therapeutics L.P., Greenfield 16 BioVentures L.P., Seven Seas Hill Corp., Ophir Green Corp., Purdue Pharma of 17 Puerto Rico, Avrio Health L.P., Purdue Pharmaceutical Products L.P., Purdue 18 Neuroscience Company, Nayatt Cove Lifescience Inc., Button Land L.P., Rhodes 19 Associates L.P., Paul Land Inc., Quidnick Land L.P., Rhodes Pharmaceuticals 20 L.P., Rhodes Technologies, UDF LP, SVC Pharma LP, SVC Pharma Inc., 21 22 Debtors. 23 ************************************* 24 25 PURDUE PHARMA, L. P., PURDUE PHARMA INC, PURDUE TRANSDERMAL 26 TECHNOLOGIES L.P., PURDUE PHARMA MANUFACTURING L.P., PURDUE 27 PHARMACEUTICALS L.P., IMBRIUM THERAPEUTICS L.P., ADLON THERAPEUTICS L.P., 28 GREENFIELD BIOVENTURES L.P., SEVEN SEAS HILL CORP., OPHIR GREEN CORP., 29 PURDUE PHARMA OF PUERTO RICO, AVRIO HEALTH L.P., PURDUE PHARMACEUTICAL 30 PRODUCTS L.P., PURDUE NEUROSCIENCE COMPANY, NAYATT COVE LIFESCIENCE

1 INC., BUTTON LAND L.P., RHODES ASSOCIATES L.P., PAUL LAND INC., QUIDNICK 2 LAND L.P., RHODES PHARMACEUTICALS L.P., RHODES TECHNOLOGIES, UDF LP, 3 SVC PHARMA LP, SVC PHARMA INC., 4 5 Debtors-Appellants-Cross-Appellees, 6 7 THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS OF PURDUE PHARMA L.P., ET 8 AL., AD HOC COMMITTEE OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION 9 CLAIMANTS, THE RAYMOND SACKLER FAMILY, AD HOC GROUP OF INDIVIDUAL 10 VICTIMS OF PURDUE PHARMA, L.P., MULTI-STATE GOVERNMENTAL ENTITIES GROUP, 11 MORTIMER-SIDE INITIAL COVERED SACKLER PERSONS, 12 13 Appellants-Cross-Appellees, 14 15 — v. — 16 17 THE CITY OF GRANDE PRAIRIE, AS REPRESENTATIVE PLAINTIFF FOR A CLASS 18 CONSISTING OF ALL CANADIAN MUNICIPALITIES, THE CITIES OF BRANTFORD, GRAND 19 PRAIRIE, LETHBRIDGE, AND WETASKIWIN, THE PETER BALLANTYNE CREE NATION, 20 ON BEHALF OF ALL CANADIAN FIRST NATIONS AND METIS PEOPLE, THE PETER 21 BALLANTYNE CREE NATION ON BEHALF ITSELF, AND THE LAC LA RONGE INDIAN 22 BAND, 23 24 Appellees-Cross Appellants, 25 26 THE STATE OF WASHINGTON, STATE OF MARYLAND, DISTRICT OF COLUMBIA, U.S. 27 TRUSTEE WILLIAM K. HARRINGTON, STATE OF CONNECTICUT, RONALD BASS, STATE 28 OF CALIFORNIA, PEOPLE OF THE STATE OF CALIFORNIA, BY AND THROUGH ATTORNEY 29 GENERAL ROB BONTA, STATE OF OREGON, STATE OF DELAWARE, BY AND THROUGH 30 ATTORNEY GENERAL JENNINGS, STATE OF RHODE ISLAND, STATE OF VERMONT, 31 ELLEN ISAACS, ON BEHALF OF PATRICK RYAN WROBLEWSKI, MARIA ECKE, ANDREW 32 ECKE, RICHARD ECKE, 33 34 Appellees. 35 _____________________________________

1 Before: NEWMAN, WESLEY, and LEE, Circuit Judges.

2 ________ 3 4 Appellants appeal from an order of the United States District Court for the 5 Southern District of New York (Colleen McMahon, J.) reversing an order of the 6 United States Bankruptcy Court for the Southern District of New York (Robert D. 7 Drain, Bankr. J.) confirming a Chapter 11 plan that included nonconsensual third- 8 party releases of direct claims against non-debtors. We hold that nonconsensual 9 third-party releases of such direct claims are statutorily permitted under 11 U.S.C. 10 §§ 105(a) and 1123(b)(6) of the Bankruptcy Code. We further conclude that this 11 Court’s case law also allows for nonconsensual third-party claim releases in 12 specific circumstances, such as those presented in this appeal. Accordingly, we 13 REVERSE the district court’s order holding that the Bankruptcy Code does not 14 permit nonconsensual third-party releases against non-debtors, AFFIRM the 15 bankruptcy court’s approval of the Plan, and REMAND the case to the district 16 court for such further proceedings as may be required, consistent with this 17 opinion. We also AFFIRM the district court’s denial of the Canadian Creditors’ 18 cross-appeal.

19 Judge Wesley concurs in the judgment in a separate opinion.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re: Purdue Pharma L.P., (2d Cir. 2023).

In Re: Purdue Pharma L.P. (In Re: Purdue Pharma L.P.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Milavetz, Gallop & Milavetz, P. A. v. United States
559 U.S. 229 (Supreme Court, 2010)
Spinelli v. City of New York
579 F.3d 160 (Second Circuit, 2009)
United States v. Johns
4 U.S. 412 (Supreme Court, 1806)
Wright v. Union Central Life Insurance
304 U.S. 502 (Supreme Court, 1938)
United States v. United States Gypsum Co.
333 U.S. 364 (Supreme Court, 1948)
Logan v. Zimmerman Brush Co.
455 U.S. 422 (Supreme Court, 1982)
United States v. Energy Resources Co.
495 U.S. 545 (Supreme Court, 1990)
Archer v. Warner
538 U.S. 314 (Supreme Court, 2003)
Tennessee Student Assistance Corporation v. Hood
541 U.S. 440 (Supreme Court, 2004)
Travelers Indemnity Co. v. Bailey
557 U.S. 137 (Supreme Court, 2009)
Monarch Life Insurance v. Ropes & Gray
65 F.3d 973 (First Circuit, 1995)
United States v. Jose Robles
45 F.3d 1 (First Circuit, 1995)
In Re: Continental Airlines
203 F.3d 203 (Third Circuit, 2000)